Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients

Allergic Diseases

Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: real life survey from a Spanish registry

Pediatr Allergy Immunol

Ibáñez-Sandín MD, Escudero C, Candón Morillo R, Lasa EM, Marchán-Martín E, Sánchez-García S, Terrados S, González Díaz C, Juste S, Martorell A, Gázquez García V, Ramírez Jiménez A, Abellán Á, Martos Calahorro MD, Tabar AI, Bartra J, García Rodríguez R, Gómez Galán C, Martín-Muñoz MF, Meseguer Arce J, Miralles JC, Montoro de Francisco AM, Poza Guedes P, Rodríguez Del Río P, OmaBASE task force (Pediatric Allergy Committee, Spanish Society of Allergy, Clinical Immunology).

doi: 10.1111/pai.13517

Immunotherapy

Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial

JAMA.

Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, Cheema AS, Leonard SA, Pongracic JA, Sauvage-Delebarre C, Assa'ad AH, de Blay F, Bird JA, Tilles SA, Boralevi F, Bourrier T, Hébert J, Green TD, Gerth van Wijk R, Knulst AC, Kanny G, Schneider LC, Kowalski ML, Dupont C

doi: 10.1001/jama.2017.16591.

Allergic DiseasesImmunotherapy

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Lancet Child Adolesc Health.

Hourihane JO, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, Nilsson C, Ibáñez MD, Deschildre A, Muraro A, Sharma V, Erlewyn-Lajeunesse M, Zubeldia JM, De Blay F, Sauvage CD, Byrne A, Chapman J, Boralevi F, DunnGalvin A, O'Neill C, Norval D, Vereda A, Skeel B, Adelman DC, du Toit G

doi: 10.

Immunotherapy

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety

Lancet.

Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, Brożek JL, Schünemann HJ

doi: 10.1016/S0140-6736

Allergic Diseases

A randomized, open-label trial of hen's egg oral immunotherapy: efficacy and humoral immune responses in 50 children

J Allergy Clin Immunol Pract

Palosuo K, Karisola P, Savinko T, Fyhrquist N, Alenius H, Mäkelä MJ

doi: 10.1016/j.jaip.2021.01.020

Psoriasis

An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA>1 at week 12

Br J Dermatol.

Papp K, Maari C, Cauthen A, Gooderham M, Spelman L, Yamanaka K, Polzer P, Zhang L, Osuntokun O, Augustin M

doi: 10.1111/bjd.18550.

Rheumatoid Arthritis

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialv

Lancet.

Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators

doi: 10.1016/

Allergic Diseases

AR101 Oral Immunotherapy for Peanut Allergy

N Engl J Med.

PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, Rachid R, Ibáñez MD, Tilles S, Assa’ad AH, Nilsson C, Rupp N, Welch MJ, Sussman G, Chinthrajah S, Blumchen K, Sher E, Spergel JM, Leickly FE, Zielen S, Wang J, Sanders GM, Wood RA, Cheema A, Bindslev-Jensen C, Leonard S, Kachru R, Johnston DT, Hampel FC Jr, Kim EH, Anagnostou A, Pongracic JA, Ben-Shoshan M, Sharma HP, Stillerman A, Windom HH, Yang WH, Muraro A, Zubeldia JM, Sharma V, Dorsey MJ, Chong HJ, Ohayon J, Bird JA, Carr TF, Siri D, Fernández-Rivas M, Jeong DK, Fleischer DM, Lieberman JA, Dubois AEJ, Tsoumani M, Ciaccio CE, Portnoy JM, Mansfield LE, Fritz SB, Lanser BJ, Matz J, Oude Elberink HNG, Varshney P, Dilly SG, Adelman DC, Burks AW

doi: 10.1056/NEJMoa1812856.

COMMENTED

Atopic Dermatitis

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study

Br J Dermatol.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E

doi: 10.1111/bjd.17932.

Related content

Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: real life survey from a Spanish registry

Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety

A randomized, open-label trial of hen's egg oral immunotherapy: efficacy and humoral immune responses in 50 children

An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA&gt;1 at week 12

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialv

AR101 Oral Immunotherapy for Peanut Allergy

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study

An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA>1 at week 12